PHASE-I HIGH-DOSE TRIAL OF I-13 I-LABELED MN-14 F(AB)(2) ANTI-CEA MABCOMBINED WITH AUTOLOGOUS BONE-MARROW SUPPORT IN PATIENTS (PTS) WITH ADVANCED MEDULLARY-THYROID CANCER (MTC)
M. Juweid et al., PHASE-I HIGH-DOSE TRIAL OF I-13 I-LABELED MN-14 F(AB)(2) ANTI-CEA MABCOMBINED WITH AUTOLOGOUS BONE-MARROW SUPPORT IN PATIENTS (PTS) WITH ADVANCED MEDULLARY-THYROID CANCER (MTC), The Journal of nuclear medicine, 38(5), 1997, pp. 168-168